Pharma cos to lose pandemic-induced pricing power in Q2 as economies reopen: Report
The pharma companies cumulatively saw their pre-tax margins rising by
306 basis points (bps) on an annualised basis and 551 bps sequentially
in the first quarter.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/pharma-cos-to-lose-pandemic-induced-pricing-power-in-q2-as-economies-reopen-report/articleshow/77719059.cms
306 basis points (bps) on an annualised basis and 551 bps sequentially
in the first quarter.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/pharma-cos-to-lose-pandemic-induced-pricing-power-in-q2-as-economies-reopen-report/articleshow/77719059.cms
Comments
Post a Comment